Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paroxetine Combined with Chemotherapy for Recurrent Ovarian Cancer
ChiCTR2500109041Phase 4Not yet recruiting
- Sponsor
- International Peace Maternity and Child Health Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paroxetine in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more, sponsored by International Peace Maternity and Child Health Hospital. Primary endpoints: Objective response rate (ORR) and Disease control rate (DCR). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
paroxetine
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)ovarian cancer
Beyond the preview
Go deeper on ChiCTR2500109041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109041.